Patients with stage IIIB/IV or recurrent NSCLC disease with nonadenocarcinoma histology received open-label figitumumab ( @ mg/kg ) plus paclitaxel ( @ mg/m ( @ ) ) and carboplatin ( area under the concentration-time curve , @ mg min/mL ) or paclitaxel and carboplatin alone once every @ weeks for up to six cycles .